Clinical impact of simultaneous complete revascularization vs. culprit only primary angioplasty in patients with st-elevation myocardial infarction and multivessel disease: A meta-analysis

Eliano Pio Navarese, Stefano De Servi, Antonino Buffon, Harry Suryapranata, Giuseppe De Luca

Research output: Contribution to journalArticle

Abstract

Primary Percutaneous Intervention (PCI) is the treatment of choice for acute ST-elevation myocardial infarction (STEMI). Nearly half of STEMI patients have multivessel (MV) disease that has been associated with worse survival. However, current guidelines recommend to treat only the culprit artery (COR) during the acute procedure. Thus, the aim of the current study was to perform a meta-analysis of trials comparing MV PCI vs. COR for STEMI patients with MV disease. Medline/CENTRAL and Web were searched for comparative studies (both randomized and non randomized trials) about MV PCI vs. COR for STEMI patients reporting mortality, re-PCI and re-MI data. Primary endpoint was 30-day mortality. The meta-analysis included 10 studies (2 randomized and 8 registries; N = 31224). As compared with COR, MV PCI significantly reduced long term rate of re-PCI (OR [95% CI] = 0.47 [0.28-0.78], P = 0.003) without increasing 30-day mortality (OR [95% CI] = 1.30 [0.79-2.12], P = 0.31) and long term re-MI (OR [95% CI] = 0.94 [0.43-2.06], P = 0.88). This meta-analysis showed safety and efficacy of MV PCI approach as compared with COR, with a significant reduction in rate of revascularizations, but no advantages in death and re-MI.

Original languageEnglish
Pages (from-to)217-225
Number of pages9
JournalJournal of Thrombosis and Thrombolysis
Volume31
Issue number2
DOIs
Publication statusPublished - Feb 2011

Fingerprint

Angioplasty
Meta-Analysis
Myocardial Infarction
Mortality
Registries
Arteries
Guidelines
Safety
Survival
ST Elevation Myocardial Infarction
Therapeutics

Keywords

  • Meta-analysis
  • Multivessel disease
  • Primary angioplasty
  • ST-elevation myocardial infarction

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Clinical impact of simultaneous complete revascularization vs. culprit only primary angioplasty in patients with st-elevation myocardial infarction and multivessel disease : A meta-analysis. / Navarese, Eliano Pio; De Servi, Stefano; Buffon, Antonino; Suryapranata, Harry; De Luca, Giuseppe.

In: Journal of Thrombosis and Thrombolysis, Vol. 31, No. 2, 02.2011, p. 217-225.

Research output: Contribution to journalArticle

@article{c9ccd837067d48cba8768d2eca27609d,
title = "Clinical impact of simultaneous complete revascularization vs. culprit only primary angioplasty in patients with st-elevation myocardial infarction and multivessel disease: A meta-analysis",
abstract = "Primary Percutaneous Intervention (PCI) is the treatment of choice for acute ST-elevation myocardial infarction (STEMI). Nearly half of STEMI patients have multivessel (MV) disease that has been associated with worse survival. However, current guidelines recommend to treat only the culprit artery (COR) during the acute procedure. Thus, the aim of the current study was to perform a meta-analysis of trials comparing MV PCI vs. COR for STEMI patients with MV disease. Medline/CENTRAL and Web were searched for comparative studies (both randomized and non randomized trials) about MV PCI vs. COR for STEMI patients reporting mortality, re-PCI and re-MI data. Primary endpoint was 30-day mortality. The meta-analysis included 10 studies (2 randomized and 8 registries; N = 31224). As compared with COR, MV PCI significantly reduced long term rate of re-PCI (OR [95{\%} CI] = 0.47 [0.28-0.78], P = 0.003) without increasing 30-day mortality (OR [95{\%} CI] = 1.30 [0.79-2.12], P = 0.31) and long term re-MI (OR [95{\%} CI] = 0.94 [0.43-2.06], P = 0.88). This meta-analysis showed safety and efficacy of MV PCI approach as compared with COR, with a significant reduction in rate of revascularizations, but no advantages in death and re-MI.",
keywords = "Meta-analysis, Multivessel disease, Primary angioplasty, ST-elevation myocardial infarction",
author = "Navarese, {Eliano Pio} and {De Servi}, Stefano and Antonino Buffon and Harry Suryapranata and {De Luca}, Giuseppe",
year = "2011",
month = "2",
doi = "10.1007/s11239-010-0510-4",
language = "English",
volume = "31",
pages = "217--225",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Clinical impact of simultaneous complete revascularization vs. culprit only primary angioplasty in patients with st-elevation myocardial infarction and multivessel disease

T2 - A meta-analysis

AU - Navarese, Eliano Pio

AU - De Servi, Stefano

AU - Buffon, Antonino

AU - Suryapranata, Harry

AU - De Luca, Giuseppe

PY - 2011/2

Y1 - 2011/2

N2 - Primary Percutaneous Intervention (PCI) is the treatment of choice for acute ST-elevation myocardial infarction (STEMI). Nearly half of STEMI patients have multivessel (MV) disease that has been associated with worse survival. However, current guidelines recommend to treat only the culprit artery (COR) during the acute procedure. Thus, the aim of the current study was to perform a meta-analysis of trials comparing MV PCI vs. COR for STEMI patients with MV disease. Medline/CENTRAL and Web were searched for comparative studies (both randomized and non randomized trials) about MV PCI vs. COR for STEMI patients reporting mortality, re-PCI and re-MI data. Primary endpoint was 30-day mortality. The meta-analysis included 10 studies (2 randomized and 8 registries; N = 31224). As compared with COR, MV PCI significantly reduced long term rate of re-PCI (OR [95% CI] = 0.47 [0.28-0.78], P = 0.003) without increasing 30-day mortality (OR [95% CI] = 1.30 [0.79-2.12], P = 0.31) and long term re-MI (OR [95% CI] = 0.94 [0.43-2.06], P = 0.88). This meta-analysis showed safety and efficacy of MV PCI approach as compared with COR, with a significant reduction in rate of revascularizations, but no advantages in death and re-MI.

AB - Primary Percutaneous Intervention (PCI) is the treatment of choice for acute ST-elevation myocardial infarction (STEMI). Nearly half of STEMI patients have multivessel (MV) disease that has been associated with worse survival. However, current guidelines recommend to treat only the culprit artery (COR) during the acute procedure. Thus, the aim of the current study was to perform a meta-analysis of trials comparing MV PCI vs. COR for STEMI patients with MV disease. Medline/CENTRAL and Web were searched for comparative studies (both randomized and non randomized trials) about MV PCI vs. COR for STEMI patients reporting mortality, re-PCI and re-MI data. Primary endpoint was 30-day mortality. The meta-analysis included 10 studies (2 randomized and 8 registries; N = 31224). As compared with COR, MV PCI significantly reduced long term rate of re-PCI (OR [95% CI] = 0.47 [0.28-0.78], P = 0.003) without increasing 30-day mortality (OR [95% CI] = 1.30 [0.79-2.12], P = 0.31) and long term re-MI (OR [95% CI] = 0.94 [0.43-2.06], P = 0.88). This meta-analysis showed safety and efficacy of MV PCI approach as compared with COR, with a significant reduction in rate of revascularizations, but no advantages in death and re-MI.

KW - Meta-analysis

KW - Multivessel disease

KW - Primary angioplasty

KW - ST-elevation myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=79951493573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951493573&partnerID=8YFLogxK

U2 - 10.1007/s11239-010-0510-4

DO - 10.1007/s11239-010-0510-4

M3 - Article

C2 - 20853136

AN - SCOPUS:79951493573

VL - 31

SP - 217

EP - 225

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 2

ER -